Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|March 2, 2019
IMA S.p.A.
IMA is world leader in the design and manufacture of automatic machines for the processing and packaging of pharmaceuticals.
IMA is world leader in the design and manufacture of automatic machines for the processing and packaging of pharmaceuticals.
At INTERPHEX 2019, visitors will have a chance to discover what’s new from IMA for the pharmaceutical industries. A special area is dedicated to IMA Digital, which represents IMA’s commitment to the evolution towards the Smart Factory and Smart Products.
Via Emilia, 428-442 - Ozzano dell’Emilia (Bologna) – Italy
tel. +39 051 6514111
INTERPHEX Booth Number: 2545
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.